Research Use Only — Confirm to Continue

OptimalDosages.com publishes reference material for laboratory and educational use. Nothing here is medical advice, a prescription, or a recommendation for human administration.

By continuing you confirm you are 21 or older and that you are accessing this material in a research or educational capacity.

Research Use Only · Dosing data compiled from published literature · Not for human or veterinary use

Adipotide Dosage & Reconstitution

FTPP, prohibitin-targeting peptidomimetic. Work out exactly what to draw for your own mix, see the doses used in research, and follow a week-by-week plan. Evidence tier: preclinical.

1Set Up Your Mix

20 mg/mL · 20000 mcg/mL
All answers assume a standard 1 mL U-100 syringe, where 1 unit = 0.01 mL. That is the usual insulin syringe and the one every number here is based on.

Your Answer — AdipotideYour Answer

2.5Draw To This Line
0.025That's This Many mL
20Doses In The Vial
0102030405060708090100 U-100 syringe · 1 mL · 100 units draw to 2.5
10 mg ÷ 0.5 mL = 20 mg/mL  →  500 mcg ÷ 20 mg/mL = 0.025 mL  →  × 100 = 2.5 units
This calculator doesn't work for Adipotide. All published Adipotide dosing is body-weight based (mg/kg) in research studies. There is no flat human dose to convert. Ignore the numbers above — read the notes further down instead.

2Week-By-Week Plan — Adipotide

not applicable
No week-by-week plan for Adipotide. This one is dosed by body weight, comes ready-mixed, or only has a single dose reported — so there is nothing to work up through.

3Common Doses — Adipotide

worked out for your mix
LevelDoseHow OftenHow Many mLDraw ToDoses In Vial
Please read this. These numbers come from published research. They are here as reference, not as instructions. A lot of them come from lab studies rather than studies in people, and some of these peptides have never been given to a person at all.

About AdipotideAbout This Peptide

Metabolic / Incretin
Also known as
FTPP, prohibitin-targeting peptidomimetic
Class
Metabolic / Incretin
Route
Subcutaneous
Half-life
Short
Evidence tier
Preclinical

A vascular-targeting peptidomimetic that ablates white adipose vasculature. Research studies showed weight loss alongside dose-dependent renal toxicity. Development did not proceed. This compound has a genuine documented harm signal.

Buy Adipotidethis peptide

Opens optimal-pep.com in a new tab

Where These Numbers Come From

Preclinical — Preclinical and in-vitro data only — no human dosing trials
A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys Barnhart KF, et al. Science Translational Medicine, 2011
The pivotal study; also the source of the nephrotoxicity finding.
Find on PubMed ↗

Newest Studies —

Not reviewed by us. This list is pulled straight from Europe PMC as papers are published. Nobody has checked whether these are any good, or whether they change anything above. The dose numbers on this page only ever change after a person reviews the evidence.

More peptides

Browse the full catalogue, or jump to a neighbouring compound.

SLU-PP-332

An estrogen-related receptor pan-agonist described as an exercise mimetic in preclinical models. Not a peptide, no human data of a…

AICAR

An AMPK-activating nucleoside studied for ischaemia protection and as an exercise mimetic in preclinical research. Requires very l…

All 71 peptides

Every compound compared in one table: dose range, how often, half-life and evidence tier.